Streetbeat News

MDGL

Madrigal Pharmaceuticals, Inc.

https://www.madrigalpharma.com

Industry

Biotechnology

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Open

328.50

Mkt cap

7.7B

Volume

382K

High

348.35

P/E Ratio

-15.90

52-wk high

377.46

Low

326.70

Div yield

N/A

52-wk low

189.00

Madrigal Pharmaceuticals has appointed Jacqualyn A. Fouse, Ph.D., to its Board of Directors, while Fred Craves, Ph.D., will retire from the board in July 2025.

Portfolio Pulse from

March 11, 2025 | 12:15 pm

Madrigal Pharmaceuticals reported better-than-expected fourth-quarter results, with earnings and revenue surpassing estimates. The strong performance was driven by robust sales of its drug, Rezdiffra, leading to a rise in MDGL stock.

Portfolio Pulse from

February 26, 2025 | 6:00 pm

Madrigal Pharmaceuticals reported a strong Q4 with a 66% increase in net sales for its drug Rezdiffra, despite a net loss of $466m in 2024. The company's cash position improved to $931m, and Rezdiffra's market potential remains significant with no competitors. Positive study data and potential European approval could enhance its market presence, making Madrigal a potential M&A target.

Portfolio Pulse from

February 26, 2025 | 5:00 pm

Madrigal Pharmaceuticals' stock surged by 15.2% as of 11:05 a.m. ET on Wednesday, indicating a significant positive market reaction.

Portfolio Pulse from

February 26, 2025 | 4:45 pm

Madrigal Pharmaceuticals (MDGL) reported a Q4 loss of $2.71 per share, which was better than the Zacks Consensus Estimate of a $4.12 loss. This is an improvement from the $5.68 loss per share reported a year ago.

Portfolio Pulse from

February 26, 2025 | 2:45 pm

Madrigal Pharmaceuticals reported its Q4 and full-year 2024 financial results and announced promising two-year data for its drug Rezdiffra™ in treating MASH cirrhosis.

Portfolio Pulse from

February 26, 2025 | 12:15 pm

Madrigal Pharmaceuticals announced positive two-year results from their Phase 3 MAESTRO-NAFLD-1 trial, showing that Rezdiffra (resmetirom) significantly reduces liver stiffness in patients with compensated MASH cirrhosis.

Portfolio Pulse from

February 26, 2025 | 11:45 am

Madrigal Pharmaceuticals will release its Q4 and full-year 2024 financial results on February 26, 2025, before the U.S. markets open.

Portfolio Pulse from

February 12, 2025 | 1:15 pm

Madrigal Pharmaceuticals' REZDIFFRA shows strong growth potential with $100-$103M in Q4 sales and a 61% growth rate. Despite potential competition, its first-mover advantage and combination use position it well. Analysts project $515M in 2025 sales, making MDGL stock a strong buy.

Portfolio Pulse from

January 19, 2025 | 2:45 pm

Madrigal Pharmaceuticals' stock fell nearly 20% this week despite positive preliminary financial results and bullish analyst updates, indicating high investor expectations.

Portfolio Pulse from

January 17, 2025 | 1:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.